A Novel Small Molecule Inhibitor of Influenza A Viruses that Targets Polymerase Function and Indirectly Induces Interferon by Ortigoza, Mila Brum et al.
A Novel Small Molecule Inhibitor of Influenza A Viruses
that Targets Polymerase Function and Indirectly Induces
Interferon
Mila Brum Ortigoza
1, Oliver Dibben
1, Jad Maamary
1, Luis Martinez-Gil
1, Victor H. Leyva-Grado
1,
Pablo Abreu Jr.
1, Juan Ayllon
1, Peter Palese
1,2, Megan L. Shaw
1*
1Department of Microbiology, Mount Sinai School of Medicine, New York, New York, United States of America, 2Department of Medicine, Mount Sinai School of
Medicine, New York, New York, United States of America
Abstract
Influenza viruses continue to pose a major public health threat worldwide and options for antiviral therapy are limited by
the emergence of drug-resistant virus strains. The antiviral cytokine, interferon (IFN) is an essential mediator of the innate
immune response and influenza viruses, like many viruses, have evolved strategies to evade this response, resulting in
increased replication and enhanced pathogenicity. A cell-based assay that monitors IFN production was developed and
applied in a high-throughput compound screen to identify molecules that restore the IFN response to influenza virus
infected cells. We report the identification of compound ASN2, which induces IFN only in the presence of influenza virus
infection. ASN2 preferentially inhibits the growth of influenza A viruses, including the 1918 H1N1, 1968 H3N2 and 2009
H1N1 pandemic strains and avian H5N1 virus. In vivo, ASN2 partially protects mice challenged with a lethal dose of influenza
A virus. Surprisingly, we found that the antiviral activity of ASN2 is not dependent on IFN production and signaling. Rather,
its IFN-inducing property appears to be an indirect effect resulting from ASN2-mediated inhibition of viral polymerase
function, and subsequent loss of the expression of the viral IFN antagonist, NS1. Moreover, we identified a single amino acid
mutation at position 499 of the influenza virus PB1 protein that confers resistance to ASN2, suggesting that PB1 is the direct
target. This two-pronged antiviral mechanism, consisting of direct inhibition of virus replication and simultaneous activation
of the host innate immune response, is a unique property not previously described for any single antiviral molecule.
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Introduction
Influenza viruses are members of the Orthomyxoviridae family [1]
and are the etiological agents of influenza, a contagious, acute, and
febrile respiratory disease. In the United States, seasonal influenza
affects approximately 5–20 percent of the population, and
influenza-related deaths range from 3,300–48,600 (average
23,600) yearly, despite the existence of vaccines and antiviral
drugs [2]. The need for effective antivirals was especially apparent
during the 2009 pandemic when they were used both therapeu-
tically and prophylactically during the period before the vaccine
became available [3]. This also precipitated the FDA to grant
temporary emergency approval to peramivir, a neuraminidase
inhibitor that is administered intravenously and therefore
beneficial for treating mechanically ventilated patients [4]. Even
in regular influenza seasons certain populations (such as the elderly
or immunocompromised) in whom vaccination response is poor,
are reliant on the availability of effective antiviral drugs to treat
infections and prevent transmission.
Currently, there are two classes of FDA-approved drugs for
treatment or chemoprophylaxis of influenza [5]. The M2
inhibitors, amantadine and rimantadine, block the activity of the
ion channel formed by M2, and thereby prevent release of viral
genome segments into the cytoplasm [6]. The rate of emergence of
viruses resistant to these drugs has been increasing globally, greatly
compromising their effectiveness. In fact, all currently circulating
influenza A virus strains (the 2009 pandemic A/H1N1 and the
seasonal A/H3N2) are resistant to M2 inhibitors [7,8,9], and
therefore these drugs are no longer recommended for the
treatment of influenza.
The other class of antiviral drugs approved for treatment of
influenza A and B infections are the neuraminidase (NA)
inhibitors, oseltamivir and zanamivir. NA inhibitors bind the
NA protein and block its enzymatic activity, thereby preventing
the efficient release of newly synthesized viruses from infected cells
[1]. A rapid rise in oseltamivir resistance was seen amongst
seasonal A/H1N1 isolates prior to the 2009 pandemic [10].
However, the novel pandemic A/H1N1 viruses, which have since
replaced the seasonal H1N1 viruses, retain oseltamivir sensitivity.
Thus, although all currently circulating influenza viruses are
susceptible to inhibition with the neuraminidase inhibitors, they
remain the only class of antiviral drug available for treatment of
influenza infections. Therefore new antiviral strategies, including
different viral targets, cellular targets or immune-modulating
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act via a new mechanism, T-705 (favipiravir) has shown the most
promise in vitro and in vivo, inhibiting influenza virus and other
RNA viruses [11,12]. T-705 becomes metabolized intracellularly
to form T-705 ribofuranosyl triphosphate, which acts as a purine
analogue and inhibits viral RNA synthesis [13].
The clinical outcome of influenza is influenced by interactions
between the virus and the host, and type I interferons (IFN-a/b)
are the primary mediators of the host innate immune response.
These cytokines are induced following virus infection and establish
an antiviral state in both infected and neighboring cells by
stimulating the expression of antiviral genes known as interferon
stimulated genes (ISGs). Due to the potent antiviral properties of
IFN-a/b and ISGs, many viruses have evolved strategies to evade
this response. Specifically, viruses often encode proteins, generi-
cally called IFN antagonists, that target pathways involved in the
production and/or response to IFN-a/b [14]. For influenza A
viruses the primary IFN antagonist is the NS1 protein [15], which
is a multifunctional protein present at high levels in infected cells.
The major role ascribed to NS1 is its ability to inhibit the IFN-a/b
response at the levels of both IFNb production and the activity of
some ISGs [15,16]. Evidence that NS1 is important for
pathogenesis comes from the finding that viruses lacking a
functional NS1 protein are attenuated and do not cause disease
[15,17,18,19,20]. These viruses are being developed as candidates
for live attenuated influenza virus vaccines [21] and by similar
reasoning, NS1 therefore represents an attractive new target for
influenza antiviral drugs [22].
Using a cell-based assay that monitors IFN-b induction, we
screened libraries of small molecular weight compounds for their
ability to restore IFN-b production to influenza A virus infected
cells. Our high-throughput screen identified a compound, ASN2,
which potentlyinhibitsinfluenzavirusbya mechanism distinctfrom
existing influenza antiviral drugs. This is the first report of an
antiviralcompoundcapable ofinhibitinginfluenzavirus polymerase
function while simultaneously activating the innate immune system.
Results
Identification of ASN2
For screening small molecular weight compounds in a high-
throughput format, it was essential to develop a primary screen
assay that was simple, fast, and robust. For this purpose, we took
advantage of an MDCK stable reporter cell line (MDCK IFNb-
luciferase) [23] which provides an easy measurement of IFN
induction. When these cells are infected with wild type influenza
virus, expression of the reporter gene is not activated due to the
presence of the virally encoded NS1 protein, which blocks virus-
induced activation of the IFNb-promoter (Fig. 1A). However,
infection with a mutant influenza virus containing a non-
functional NS1 protein (rPR8 NS1-113 [21]) results in robust
activation of the reporter. The screen assay consisted of infection
of the MDCK IFNb-luciferase reporter cells with wild type
influenza A/PR/8/34 virus in the presence of the library
compounds, with the aim of identifying those that restore the
IFNb response.
The primary screen assay was initially optimized in a 96-well
format and further miniaturized into 384-well format. We verified
its suitability for use in a high-throughput screen by the following
parameters: a Z9 factor of 0.5 [24], coefficient of variation (CV) of
16.6460.07, signal-to-background ratio (S/B) of 84.6960.45, and
signal-to-noise ratio (S/N) of 5.9460.02. A library of 84,551
structurally diverse compounds was screened in duplicate at the
National Screening Laboratory for the Regional Centers of
Excellence in Biodefense and Emerging Infectious Diseases
(NSRB) (Harvard Medical School) and hits were identified based
on an increase in luciferase signal. The results from the primary
screen were standardized by calculating a Z-Score for each
compound (Fig. S1). Hit compounds were selected based on
minimum Z-Scores of 3 and 2.5 from duplicate samples, which
resulted in the identification of 264 primary hits (0.3%).
Secondary screen assays were performed in order to confirm the
hits identified in the primary screen. Every hit compound was
tested in a 10-point dose-response curve both in the presence and
absence of influenza virus infection in order to distinguish between
those compounds that induce IFNb independently of a virus
stimulus versus those that require virus infection. This was in
contrast to the primary screen, in which each compound was
tested at a single concentration (350 fold dilution of the stock
concentration, see methods), and only in the presence of influenza
virus infection. A compound was confirmed as a hit if it displayed
a dose-dependent effect with a minimum 5 fold induction either in
the presence or absence of influenza virus infection. This process
resulted in the selection of 27 compounds, of which 25 induced
IFNb induction independently of virus infection and two induced
IFNb induction only in the presence of virus infection. Since the
latter two compounds are likely to induce a specific antiviral
immune response only in infected cells, thus limiting the
undesirable side effects associated with IFN therapy, these were
pursued for further characterization. We selected ASN2 (Fig. 1B)
as our lead compound since this compound produced a more
robust IFN response.
To explore the requirement for an influenza virus-specific
stimulus, we tested the ability of ASN2 to induce IFNb expression
in the presence of an influenza virus and a non-influenza virus,
vesicular stomatitis virus (VSV). ASN2 was able to induce IFNb in
the presence of influenza A/PR/8/34 virus but not VSV (Fig. 1C),
suggesting that this compound requires an influenza virus-specific
stimulus in order to induce IFNb.
ASN2 induces an antiviral response during influenza A
virus infection
To verify that the IFNb-luciferase reporter induction observed
in the primary and secondary screens correlates with induction of
IFNb mRNA and associated IFN-stimulated genes (ISG) in
human cells, we infected human lung carcinoma (A549) cells with
Author Summary
Influenza viruses are rapidly developing resistance against
available anti-influenza drugs and consequently there is an
urgent demand for new treatment approaches. We
identified compound ASN2 in a high-throughput screen
for molecules that are capable of inducing the antiviral
cytokine interferon (IFN) in the presence of influenza virus
infection. Normally, influenza virus blocks IFN production,
an activity that is dependent on the viral NS1 protein and
contributes to the ability of the virus to cause disease in an
infected host. We show that ASN2 is a potent inhibitor of
influenza A virus and can partially protect infected animals
from disease and death. ASN2 acts by targeting influenza
virus polymerase function which results in inhibition of
virus replication, and as a consequence, NS1 expression.
Thus the ability of ASN2 to induce IFN is a ‘‘side-effect’’,
albeit a desirable one, of polymerase inhibition. This
combination of directly inhibiting the virus while also
stimulating the host immune response is a novel property
for an antiviral compound.
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DMSO, and examined expression of IFN-related genes by qRT-
PCR. IFNb, ISG56 (IFIT1), and IP10 (CXCL10) mRNAs were
significantly induced in the infected sample treated with ASN2,
and this induction increased over time (Fig. 2A). Other genes
tested by qRT-PCR showed similar patterns of induction in the
presence of ASN2, including IFNl-1, -2, -3, CCL5, IRF7, ISG54,
MxA, PKR, and STAT1 (data not shown).
To explore whether the cytokines released during ASN2
treatment of influenza virus infected cells are able to induce a
protective antiviral response, we performed an antiviral bioassay.
A549 cells were infected with influenza virus and treated with
ASN2 or DMSO. Infection with Sendai virus (SeV) Cantell was
used as a positive control for interferon induction [25].
Supernatants were collected at 24 hours, UV-inactivated and
then transferred to naı ¨ve VERO cells (which are defective for
production of interferon but sensitive to the action of exogenous
interferon [26,27,28]), for 24 hours prior to infection with
Newcastle disease virus expressing a GFP reporter (NDV-GFP).
If the supernatants contain cytokines capable of inducing an
antiviral state, subsequent infection with NDV-GFP would be
restricted; otherwise, growth of NDV-GFP would be expected to
proceed uninhibited. Supernatants from influenza virus infected
cells treated with ASN2 were capable of restricting NDV-GFP
growth in VERO cells, and this effect was directly proportional to
the dose of ASN2 (Fig. 2B). As expected, supernatants from
influenza virus infected cells treated with DMSO did not restrict
growth of NDV-GFP as wild-type influenza virus infection does
not induce significant levels of IFNb. Notably, supernatants from
uninfected ASN2-treated cells only showed minimal ability to
restrict the growth of NDV-GFP. As this assay measures general
antiviral cytokine responses, not only type I IFN, it is possible that
ASN2 is capable of inducing some non-IFN cytokines that account
for the observed 20% inhibition of NDV-GFP. Overall these data
indicate that only cells both infected with influenza virus and
treated with ASN2 are capable of releasing cytokines that induce a
robust antiviral state in VERO cells.
To further understand the transcriptional profile of genes
affected by ASN2 treatment, we performed deep sequencing of
total mRNA from A549 cells infected with influenza A/WSN/33
virus and treated with either ASN2 or DMSO. The total number
of sequence reads for each gene was normalized to that of
GAPDH for each sample, since this gene was unaffected by ASN2
and was one of the most abundant. We compared a total of 15,154
genes and 34 of them were induced at least 100 fold in the ASN2
sample over the DMSO control (Table S1). Amongst these
induced genes are several known ISGs (Fig. 2C), and notably,
several have been described to participate in the innate immune
response to viral pathogens (e.g. Mx, OAS, IFIH1 (MDA5), BST2
(tetherin), DDX58 (RIGI)). This analysis further demonstrated the
ability of ASN2 to induce the expression of genes that are
associated with the innate immune response.
Figure 1. Concept for high-throughput compound screen and identification of ASN2. (A) MDCK cells stably expressing IFNb-luciferase
reporter are not responsive to wild type (wt) influenza A virus infection due to the presence of a fully functional NS1 protein (left panel). Infection
with a mutant virus expressing a truncated NS1 protein (rPR8 NS1-113), which is unable to antagonize the IFNb production pathway, can induce the
IFNb-luciferase reporter (middle panel). The HTS assay consisted of infecting the reporter cells with wt influenza A virus in the presence of small
molecular weight compounds. The aim was to identify compounds that are able to restore IFNb in the presence of wt influenza A virus (right panel).
(B) Chemical structure of ASN2 with its molecular weight (MW) and chemical formula. (C) Reporter assays of MDCK IFNb-luciferase cells treated with
increasing concentrations of ASN2 for 2 hours prior to mock infection or infection with influenza A/PR/8/34 virus and VSV-GFP. Luciferase activity was
assayed 18 hours post infection. Curves represent the mean of triplicate values 6 standard deviation.
doi:10.1371/journal.ppat.1002668.g001
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mediated induction of IFNb, an infection with UV-inactivated
influenza virus was performed. Indeed, ASN2 was incapable of
inducing IFNb and ISG56 mRNA in the presence of UV-
inactivated influenza A virus, contrary to its effect in the presence
of a replication-competent virus (Fig. S2). This indicated a
necessity for virus replication in the IFNb-inducing activity of
ASN2.
Antiviral activity of ASN2
To assess its potential to inhibit virus replication, ASN2 was
tested at non-cytotoxic concentrations in a viral replication assay.
A549 cells were infected with influenza A/WSN/33 virus
(MOI=0.01) and treated with ASN2 at a range of concentrations
for 48 hours. A reduction in viral titers of 4.5 logs was detected in
the presence of 50 mM ASN2, and the IC50 (concentration of 50%
inhibition) was determined to be 3 mM (Fig. 3A). The CC50
(concentration of 50% cytotoxicity) for ASN2 is 300.9 mM,
resulting in a selective index (SI=CC50/IC50) of 100.3. Several
strains of influenza A and B viruses as well as non-influenza viruses
(VSV and Sindbis virus) were tested against ASN2. Interestingly,
ASN2 was significantly more potent against influenza A viruses,
including a number of strains of H1N1, H3N2, and H5N1
subtypes, and it inhibited the reconstructed virus from the 1918
pandemic very efficiently, reducing viral titers by up to 6.2 logs
(Table 1). We note that for non-influenza A viruses, ASN2 does
display some antiviral activity but that it is far more effective
against influenza A viruses. We hypothesize that this non-specific
antiviral effect may be related to the minor induction of antiviral
cytokines by ASN2 observed in the antiviral bioassay (Fig. 2B).
To evaluate the activity and potency of ASN2 in vivo, BALB/c
mice were treated with ASN2 (100 mg/kg/day) every 8 hours for
eight days. The first dose was given 8 hours prior to infection with
5MLD50 of influenza A/WSN/33 virus. PBS-treated and solvent-
treated infected animals succumbed to infection at 9 days post-
infection (0% survival), while the uninfected group and oseltami-
vir-treated group (1.5 mg/kg/day) displayed 100% survival
(Fig. 3B). The ASN2-treated animals exhibited significantly less
weight loss compared to the PBS-treated and solvent-treated
infected animals and this resulted in a delayed time-to-death with
33% surviving up to 20 days post infection. Mice from each group
were euthanized on days 3 and 8 post infection and lungs were
harvested to determine viral titers. Except for the oseltamivir-
treated group, no significant differences in lung titers were
observed (data not shown). The limited performance of ASN2 in
vivo is perhaps explained by metabolic instability. An in vitro mouse
Figure 2. ASN2 induces an antiviral response during influenza A virus infection. (A) qRT-PCR analysis of IFNb, ISG56 and IP10 transcripts in
A549 cells infected with influenza A/WSN/33 virus (MOI=1) and treated with ASN2 (50 mM) for 24 hours. Values were normalized to a-tubulin for
each sample and are represented as fold induction over uninfected DMSO-treated sample (MOCK). Error bars reflect standard deviation of fold
change. p,0.05, **p,0.005, ***p,0.0005 (B) Antiviral bioassay analysis of A549 cells infected with influenza A virus and treated with ASN2 for
18 hours. Supernatants from these cells were collected and UV-inactivated prior to overlaying them onto freshly plated VERO cells for a 24 hour
incubation period prior to infection with NDV-GFP. Graphs represent percent inhibition of NDV-GFP induced by the supernatants collected from the
indicated treatments. Percentage inhibition induced by supernatants from Sendai virus (SeV) infection was set to 100%. Bars represent mean of
triplicate values 6 standard deviation. (C) Deep sequencing analysis of mRNA from A549 cells infected with A/WSN/33 (MOI=1) and treated with
DMSO or ASN2 (50 mM) for 24 hours. The total number of reads obtained for the indicated genes for DMSO and ASN2 treatments are shown.
*p,0.05.
doi:10.1371/journal.ppat.1002668.g002
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ASN2 and the results showed a high intrinsic hepatic clearance
(CLint) of 224 mL/min/mg protein (normal levels being 8.8–
48 mL/min/mg protein), and a very short half-life (t1/2)o f
6.18 min. Collectively, these results show that ASN2 partially
protects mice from lethal influenza A virus infection, and suggest
that the pharmacokinetic properties of ASN2 could be optimized
to further improve in vivo efficacy.
ASN2 targets influenza A virus polymerase function
To determine the contribution of IFN to the antiviral activity of
ASN2, we performed virus inhibition assays in A549 cells and
VERO cells simultaneously. Cells were infected with influenza A/
WSN/33 virus (MOI=0.01) and then treated with increasing
concentrations of ASN2 for 48 hours prior to measuring virus
titers in the supernatants. Surprisingly, antiviral activity was still
observed in VERO cells, which are known to be defective for the
production of type I IFN, with negligible differences in their IC50
and IC99 concentrations as compared to A549 cells (Fig. 4A). The
same results were obtained when using an even lower multiplicity
(MOI=0.0001) in A549 and VERO cells, which should have
allowed for any IFN-mediated inhibition to be observed (data not
shown). Moreover, ASN2 also retained full activity in cells
deficient in IRF9, STAT1, or STAT2 (data not shown). These
results suggest that the antiviral activity of ASN2 in tissue culture is
independent of IFN activity.
Due to the role of the influenza A virus NS1 protein as a potent
IFN antagonist and facilitator of viral replication, we investigated
the involvement of this protein in the antiviral activity of ASN2.
VERO cells were infected with wild type influenza A/PR/8/34
virus or a virus lacking NS1 (PR8DNS1) in the presence of DMSO
or ASN2. ASN2 treatment significantly reduced the number of
plaques relative to DMSO treatment for both wild type and DNS1
viruses (Fig. 4B), suggesting that NS1 is not a direct target of
ASN2.
We next explored viral protein expression in influenza virus
infected cells under conditions where IFNb induction is observed
in the presence of ASN2. A549 cells were infected with influenza
A/WSN/33 virus (MOI=1) and treated with 50 mM ASN2 for
24 hours. Western blot analysis revealed decreased expression of
all viral proteins examined but this decrease was much more
apparent for the NS1, M1 and M2 proteins (Fig. 4C). To associate
this loss of NS1 expression with the induction of IFNb observed
during ASN2 treatment, NS1 was expressed from plasmid in A549
cells infected with influenza virus and treated with ASN2. Infected
cells transfected with empty plasmid displayed induction of IFNb
in the presence of ASN2 and not DMSO, as seen previously
(Fig. 4D). On the contrary, IFNb induction was not observed in
ASN2-treated infected cells overexpressing NS1. Furthermore,
dilution of the NS1 plasmid resulted in dose-dependent restoration
of IFNb induction in these cells. These findings suggest that the
loss of NS1 expression, which results from ASN2-mediated virus
inhibition, is responsible for the observed induction of IFNb.
Given that ASN2 treatment resulted in decreased viral protein
expression, the effect of ASN2 on replication and/or transcription
of viral RNA was investigated. An influenza virus mini-genome
assay, which measures the activity of the viral polymerase complex
in the context of a reconstituted viral ribonucleoprotein, was
performed in the presence or absence of ASN2. A549 cells were
co-transfected with expression plasmids for the influenza A/
WSN/33 virus polymerase proteins (PB1, PB2, and PA), the
nucleoprotein (NP), an influenza virus-specific luciferase reporter
plasmid [29], and a transfection control plasmid. ASN2 or DMSO
was added and the transfection allowed to proceed for 24 hours
Figure 3. ASN2 inhibits the replication of influenza A virus and
displays in vivo antiviral activity. (A) Virus titers from A549 cells
infected with influenza A/WSN/33 virus (MOI=0.01) and treated with
increasing concentrations of ASN2 for 48 hours (orange curve). Cell
viability analysis of A549 cells treated with increasing concentrations of
ASN2 for 48 hours (black curve). Curves represent means of triplicate
values 6 standard deviation. (B) Bodyweight and survival curves of
BALB/c mice (groups of 9) infected with influenza A/WSN/33 virus
(5LD50) and treated with 100 mg/kg of ASN2 every 8 hours for 8 days.
Compound was delivered intraperitoneally beginning 8 hr prior to
infection. Three mice from each group were sacrificed on days 3 and 8
post infection to determine viral lung titers (data not shown). Curves
represent means 6 standard deviation, *p,0.001. Mice that fell below
75% of their initial weight were sacrificed in accordance with our animal
protocol.
doi:10.1371/journal.ppat.1002668.g003
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influenza virus mini-genome reporter in a dose-dependent manner
without affecting expression of the control reporter, suggesting that
the function of the influenza virus polymerase was affected by
ASN2 (Fig. 5A).
These findings were complemented by performing primer
extension assays to analyze the effect of ASN2 on different
influenza virus RNA species. A549 cells were infected with
influenza A/WSN/33 virus (MOI=5) and treated with ASN2 for
6 hours prior to harvesting total RNA. Production of mRNA and
vRNA from three representative segments of the influenza
genome, PB2, NA, and NS, was analyzed. Treatment with
ribavirin was included as a control. For all three segments, vRNA
synthesis was inhibited by ASN2 in a dose-dependent manner,
whereas mRNA synthesis was decreased in the NA and NS
segments but not in the PB2 segment (Fig. 5B). In contrast, the
ribavirin control inhibited all three segments to an equal extent.
From these results we propose that ASN2 inhibits polymerase
function in a manner that inhibits vRNA synthesis from all
segments and that it also perturbs mRNA production but possibly
in a segment-specific manner.
The effects of ASN2 on viral mRNA synthesis were verified by
analyzing the transcriptional profile of viral mRNA obtained by
deep sequencing of infected cells treated with ASN2 or DMSO, as
described previously. A striking segment-dependent effect on the
production of viral mRNA in the ASN2-treated sample was
observed (Fig. S3). Notably, transcription from the smaller
segments, M and NS, was inhibited to the greatest extent, which
correlated with the results from the primer extension and western
blot assays showing that mRNA and protein levels from smaller
segments were more strongly affected by ASN2 treatment than
those from larger ones. An apparent increase in mRNA expression
was seen with the larger segments (PB2, PB1, PA) in the presence
of ASN2 (Fig. S3).
To determine if the ASN2 target is a viral protein, we attempted
to select for an ASN2 escape mutant influenza virus. A resistant
virus was isolated in four passages and complete sequencing of the
viral genome revealed a single amino acid change from a tyrosine
(Y) to a histidine (H) at position 499 of the PB1 protein (PB1-
Y499H). To confirm that the PB1-Y499H mutation indeed
conferred resistance to ASN2, we engineered this mutation into
a recombinant influenza A/WSN/33 virus (rWSN PB1-Y499H)
using reverse genetics [30]. The PB1-Y499H mutation did not
interfere with the normal growth properties of the virus (data not
shown) and unlike the wild type virus, rWSN PB1-Y499H was
resistant to ASN2 treatment (Fig. 6A–B).. Furthermore, the
expression profiles of IFNb, ISG56, M1, and NS1 mRNA were
unaffected by ASN2 treatment of cells infected with the rWSN
PB1-Y499H virus, whereas an induction of IFNb and ISG56, and
inhibition of M1 and NS1 was observed in the presence rWSN
infection (Fig. 6C–D).
To verify that the PB1-Y499H mutation conferred resistance to
ASN2 by restoring normal viral RNA synthesis, we performed an
influenza virus mini-genome assay using vRNPs reconstituted with
either wild type PB1 or PB1-Y499H. ASN2 inhibited polymerase
function in the mini-genome assay using the wild type PB1, but not
the PB1-Y499H mutant protein (Fig. 6E). Collectively, these
findings confirmed that ASN2 resistance was conferred by a single
amino acid mutation in the PB1 protein and strongly suggested
that the viral target of ASN2 was the influenza A virus PB1
protein.
We examined the conservation of residue 499 among several
human influenza A viruses using the influenza virus research
database (IRD) [31]. Over 6,000 viruses from three different
influenza A virus subtypes were analyzed, and the majority either
contained a serine (S) or a tyrosine (Y) at position 499 of the PB1
protein, with exception of one A/H3N2 virus which contained a
phenylalanine (F) (Table S2). This indicates that residue 499 of
PB1 is highly conserved among influenza A viruses, which
correlates with the ability of ASN2 to inhibit all influenza A
viruses examined in this study. The corresponding amino acid
position in the PB1 protein of influenza B viruses is an aspartic
acid (D498), which may explain the relatively inefficient ASN2
antiviral activity observed with influenza B virus (Table 1).
Surprisingly, it was found that mutation of residue D498 to Y
rendered the influenza B virus polymerase sensitive to inhibition
Table 1. Viruses tested against ASN2.
Virus Strain IC50 (mM) IC99 (mM) Selective Index (CC50/IC50) Inhibition at 50 mM (log10)
Influenza Viruses
rA/Brevig Mission/1/1918 (H1N1)* 3 13.5 100.3 6.2
A/WSN/1933 (H1N1) 3 20 100.3 4.6
rA/Puerto Rico/8/1934 (H1N1) 4 24 75.3 2.4
A/Hong Kong/1/1968 (H3N2) 3 6 100.3 4.4
A/Udorn/307/1972 (H1N1) 3.5 14 86 4.7
A/USSR/90/1977 (H1N1) 4.2 13 71.6 3.2
A/swine/Texas/4199-2/1998 (H3N2) 3 12.5 100.3 4.2
rA/Vietnam/1203/2004 (H5N1)** 4 12 75.3 4.6
A/California/04/2009 (H1N1) 3 40 100.3 2.2
B/Yamagata/16/1988 14 N/A 21.5 0.3
Non-Influenza Viruses
Vesicular Stomatitis Virus 5 52 60.2 1.6
Sindbis Virus*** 48 .50 6.5 0.2
*HA segment from A/South Carolina/1/1918.
**Low pathogenicity mutant (deleted polybasic cleavage site in HA).
***Experiment done in VERO cells.
doi:10.1371/journal.ppat.1002668.t001
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mutant polymerase was less active than that containing the wild-
type PB1.
Examination of this amino acid position in polymerases of all
segmented negative strand RNA viruses shows that it is in close
proximity (5 residues downstream) to Motif E, which is a highly
conserved region [32]. Nevertheless, the residue at this position
differs between viruses, with no other virus possessing a tyrosine or
a serine as do influenza A viruses. Again, this correlates with our
finding that ASN2 is more specific for influenza A viruses.
Discussion
We developed a cell-based high-throughput screen assay that
identifies small molecular weight compounds which are able to
restore the endogenous antiviral response to influenza virus
infected cells. In this process, we identified two groups of IFNb-
inducing compounds. The first group includes 25 compounds that
induce IFNb independently of a virus stimulus while the second
group consists of two compounds that induce IFNb only in the
presence of virus. From the latter group, ASN2 was chosen as a
lead compound because of its superior ability to induce the
expression of type I IFN and ISGs, and thereby establish an
antiviral state; a desirable feature of antiviral drugs directed
against viruses that are sensitive to the effects of IFN. This
response is very specific for influenza virus and requires virus
replication. Transcriptional profiling of influenza virus infected
cells treated with ASN2 confirmed the ability of this compound to
induce a myriad of genes, many of which are known ISGs with
potent antiviral function. However, a more in-depth analysis of
these data will be necessary to fully understand the spectrum of
cellular genes induced by ASN2 that may contribute to its antiviral
activity. In addition, we confirmed the biological activity of the
ASN2-induced cytokines in an antiviral bioassay, indicating that
this response is capable of protecting neighboring, uninfected cells.
ASN2 has potent antiviral activity against multiple subtypes of
influenza A virus, including several pandemic strains that have
been associated with severe human disease. This antiviral activity
mediates partial protection of mice from a lethal dose of influenza
A virus, a feature that can probably be improved further with
medicinal chemistry optimization of ASN2 to provide optimal
pharmacokinetic properties. Given the strong IFN-inducing ability
of ASN2 we were particularly surprised to find that the compound
retained its antiviral activity in Vero cells, indicating that its
antiviral mechanism is independent of type I IFN. Thus it
appeared that the activation of an innate immune response was
secondary to a more direct antiviral function. The ability of ASN2
to inhibit influenza virus mini-genome activity suggested that viral
polymerase function may be the target of the compound.
Generation of an ASN2 resistant virus revealed the importance
of a tyrosine residue at position 499 of the PB1 protein for ASN2
antiviral activity.
Position 499 of the PB1 protein is occupied by either a tyrosine
or a serine in virtually all influenza A virus strains, but not in the
Figure 4. Antiviral activity of ASN2 is independent of
interferon production and NS1. (A) Virus titers from A549 and
VERO cells infected with influenza A/WSN/33 virus (MOI=0.01) and
treated with increasing concentrations of ASN2 (6.25–50 mM) for
48 hours. (B) Plaque-reduction analysis of VERO cells infected with the
indicated viruses in the presence of either DMSO or ASN2 (50 or 25 mM).
Plaques were immunostained using an NP antibody. (C) Western blot
analysis of cellular extracts from A549 cells infected with influenza A/
WSN/33 virus (MOI=1) and treated with ASN2 (50 mM) for 24 hours.
Specific antibodies were used for each of the indicated proteins. (D)
Reporter assay analysis of A549 cells transfected with IFNb-luciferase
and pRL-TK reporters, empty plasmid (-) or decreasing concentrations of
NS1 (325, 32.5, and 3.25 ng) for 24 hours prior to infection with
influenza A/WSN/33 virus (MOI=1). Cells were treated with either ASN2
(50 mM) or DMSO and luciferase activity was determined 24 hours post
infection. Values were normalized to Renilla luciferase activity for each
sample and are represented as fold induction over uninfected DMSO-
treated sample (mock). Bars represent means of triplicate values 6
standard deviation.
doi:10.1371/journal.ppat.1002668.g004
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ing the PB1 proteins of influenza B and C viruses, which have an
aspartic acid and a glycine, respectively in this position. This
variability explains the observed spectrum of ASN2 antiviral
activity and we demonstrated that the influenza B virus
polymerase, which is naturally insensitive to ASN2, can be made
to be ASN2-sensitive by simple substitution of a tyrosine for the
wild-type aspartic acid. It is tempting to speculate that the
requirement for a tyrosine or serine residue is an indication that
these residues are targets for phosphorylation and that ASN2
somehow interferes with this modification, although the presence
of histidine in the resistant mutant may not support this theory. Of
note, PB1 is reported to be phosphorylated by protein kinase C,
but the target residue has not been identified [33]. Nevertheless,
our data definitely suggest a functional role for this particular
region of the PB1 protein, which has not been elucidated to date.
The rapid generation of resistance is a strong indication that PB1
is the direct target of ASN2 (as opposed to a cellular protein) but
this will have to be formally proven with in vitro binding assays.
Unfortunately this region of PB1 is not covered by the available
crystal structures of PB1 so in silico modeling attempts are not
possible at this time.
Despite the inhibitory effects of ASN2 on polymerase function
in the mini-genome assay, when viral gene expression was
analyzed at the level of both mRNA and protein it was clear
that not all genes are equally affected. In particular, expression of
genes encoded by the smallest genome segments, M and NS, are
more severely inhibited. The suppression of NS1 protein
expression immediately led us to question whether this was the
cause of ASN2-mediated IFN induction and supplementation with
plasmid-expressed NS1 showed that this is indeed the case. Thus,
the induction of IFN observed in ASN2-treated influenza virus
infected cells appears to be due to loss of NS1 expression, which is
secondary to a specific inhibitory effect of ASN2 on viral
polymerase function. Obviously it will be important to assess the
consequences of reduced M1, M2, and NEP expression as well
and determine how they may contribute to the antiviral activity of
ASN2. In particular, NEP has been shown to be a key regulator of
viral transcription and replication, and lack of NEP may facilitate
the antiviral actions of ASN2, possibly through its role in the
production of svRNAs [34,35].
To our knowledge, differential viral gene expression based on
segment length has not been described for influenza virus. Rather,
it has been reported that some genes are preferentially expressed
early (NP and NS1) and others late in infection (M1) [36,37],
however this pattern clearly does not correlate with what we
observed in the presence of ASN2 where there was preferential
downregulation of mRNAs expressed from the smaller segments
(M1, M2, NS1, NEP). This effect seems to be specific for
transcription as no segment-dependent inhibition of vRNA
synthesis was observed. Although the M and NS segments are
coincidentally also the ones that produce spliced products, we do
not think that ASN2 is specifically affecting splicing as we observe
similar decreases in proteins expressed from both spliced (M2,
NEP) and unspliced (M1, NS1) transcripts. In the absence of a
better understanding of viral transcription regulation it is difficult
Figure 5. ASN2 inhibits viral RNA synthesis. (A) Influenza A virus mini-genome activity in A549 cells transfected with the influenza virus firefly
luciferase mini-genome reporter, pRL-TK control reporter, PB1, PB2, PA, and NP protein expressing plasmids. Treatment with DMSO or increasing
concentrations of ASN2 (6.25–50 mM) was performed during transfection. Luciferase activity was assayed 24 hours post transfection. Firefly and
Renilla luciferase values are represented as % activity from the mock (minigenome without NP expression) relative to the DMSO control. Error bars
reflect the standard deviation of % activity. (B) Primer extension analysis of influenza virus mRNA and vRNA from A549 cells infected with influenza A/
WSN/33 virus (MOI=5) and treated with DMSO or decreasing concentrations of ASN2 (50–12.5 mM) for 6 hours. PB2, NA, and NS segments were
analyzed. Ribavirin (100 mM) was used as a positive control and 5S rRNA was used as a loading control. Quantification of mRNA and vRNA expression,
normalized to 5S rRNA, is shown on the right.
doi:10.1371/journal.ppat.1002668.g005
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one of the smaller viral gene products) in regulating mRNA
synthesis in a segment-dependent manner. In that sense ASN2
could serve as a useful tool to investigate this phenomenon further.
It should be noted that the ability to select for an ASN2-
resistant mutant in tissue culture does not necessarily impact
negatively on the future of ASN2 as an antiviral drug candidate.
Similar findings have been reported with oseltamivir which is a
very successful influenza virus drug [38,39]. Furthermore, it is
likely that future influenza therapies will involve combinations of
drugs that act via distinct mechanisms, thereby reducing the
chances of drug resistance. In this respect, the identification of
ASN2 as a polymerase inhibitor complements the current class of
neuraminidase inhibitors. To date, there has been only one other
report of an influenza antiviral compound targeting PB1 [40].
This compound differs structurally from ASN2 and also
generates a different resistance mutation (H456P), but without
a three dimensional structure we cannot predict whether amino
acids 499 and 456 are in close proximity. The type I IFN-
inducing capacity of ASN2 is a unique property for a virus-
directed compound and combines both viral inhibitory activity
and immune activation activity in one molecule. We believe that
the ability of ASN2 to preferentially inhibit NS1 expression is the
reason for its IFN induction properties and that other inhibitors
of influenza virus polymerase function that act equally on all
segments will not induce IFN. In short, ASN2 produces an
imbalance in the synthesis of RIG-I-stimulating RNA versus
NS1, whereas antiviral compounds affecting all segments
suppress both the production of RIG-I stimulus and NS1. In
support, we have shown that A3, a broad-spectrum antiviral
compound that depletes pyrimidine pools and prevents all viral
RNA synthesis [41], does not induce IFN (Fig. S4). Although not
essential for antiviral action in tissue culture, IFN induction may
prove to be beneficial in an in vivo setting, possibly facilitating
activation of the adaptive immune response and viral clearance,
which will be explored further using IFNAR
2/2 mice. The
targeted production of IFN (i.e. only occurring in influenza virus
infected cells) also provides distinct advantages over exogenous
Figure 6. A Y499H mutation in the PB1 protein confers resistance to ASN2. (A) Plaque-reduction analysis of MDCK cells infected with the
indicated viruses in the presence of either DMSO or ASN2 (50 mM). Plaques were stained with an anti-NP antibody. (B) Virus titers from MDCK cells
infected with the indicated viruses and treated with increasing concentrations of ASN2 for 48 hours. Curves represent means of triplicate values 6
standard deviation. (C–D) qRT-PCR analysis of IFNb, ISG56, NS1 and M1 mRNAs from A549 cells infected with the indicated viruses (MOI=1) and
treated with ASN2 (50 mM) for 24 hours. Values in (C) were normalized to a-tubulin for each sample and are represented as fold induction over
uninfected DMSO-treated sample. Values in (D) are represented as fold induction over the infected DMSO-treated sample. Error bars reflect standard
deviation of fold change. (E) Influenza A virus mini-genome activity in 293T cells transfected with the influenza A virus mini-genome reporter, pRL-TK
control reporter, wtPB1 or PB1-Y499H, PB2, PA, and NP protein expressing plasmids. Treatment with DMSO or increasing concentrations of ASN2
(12.5–50 mM) was performed during transfection. Luciferase activity was assayed 24 hours post transfection. Values were normalized to Renilla
luciferase activity for each sample and are represented as % activity relative to the control (minigenome without PB1 expression). Error bars reflect
the standard deviation of % activity. (F) Influenza B virus mini-genome activity in A549 cells transfected with the influenza B virus mini-genome CAT
reporter, pRL-TK control reporter, wtPB1 or PB1-D498Y, PB2, PA, and NP protein expressing plasmids. Cells were treated with DMSO or 50 mM ASN2.
CAT and luciferase activities were measured 24 hrs post transfection and normalized % mini-genome activity for the wt or mutant PB1 is shown
relative to the DMSO control in each case.
doi:10.1371/journal.ppat.1002668.g006
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Materials and Methods
Cell culture and reagents
Madin-Darby canine kidney (MDCK) epithelial cells, human
alveolar epithelial (A549) cells, human embryonic kidney 293T
(293T) cells, and African green monkey kidney cells (VERO) cells,
wereobtained from the AmericanType Culture Collection(ATCC,
Manassas, VA). MDCK stably expressing the IFNb-luciferase
reporter (MDCK IFNb-luciferase) [23] were kindly provided by
Adolfo Garcia-Sastre (Mount Sinai School of Medicine, New York,
NY). MDCK, A549, 293T, and VERO cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS) (HyClone,
South Logan, UT), and 1% penicillin-streptomycin (P/S) (Gibco).
MDCK IFNb-luciferase cells were cultured in DMEM supple-
mented with 10% FBS, 1% P/S, 0.5 mg/mL Hygromycin B
(Invitrogen, Carlsbad, CA), and 2 mg/mL Geneticin (Invitrogen).
All cells were grown at 37uC, 5% CO2.
Treatment of cells with human b interferon (IFNb) (PBL
Interferon Source, Piscataway, NJ) was performed as described in
the text. Transfection of DNA and RNA was performed in Opti-
MEM I-reduced serum medium (Opti-MEM) (Gibco) with
Lipofectamine LTX (Invitrogen) in A549 cells according to
manufacturer’s specifications. For measurement of luciferase
production in reporter assays, the Dual-Glo Luciferase Assay
System (Promega, Fitchburg, WI) was used. The Bright-Glo
Luciferase Assay System was used in the high-throughput primary
screen and confirmation screen (Promega, Fitchburg, WI).
Expression plasmids and cloning
The pRL-TK (Promega) reporter contains a Renilla luciferase
gene under the regulation of the herpes simplex virus thymidine
kinase promoter. Mammalian expression plasmids encoding the
WSN NS1 protein and the firefly luciferase reporter (pGL4.17,
Promega) under the regulation of the IFNb promoter (IFNb-
LUC), were kindly provided by Adolfo Garcia-Sastre (Mount Sinai
School of Medicine, New York, NY). The influenza A virus
minigenome reporter (pPolI NP_Luc) was generated as previously
described [29].
The influenza virus rescue plasmid pPolI-PB1 Y499H was
generated by exchanging one nucleotide in the parental plasmid
pPolI-PB1 using the QuickChange site-directed mutagenesis kit
(Agilent Technologies, Wilmington, DE) using specific primers
(forward: 59-CACAAGTTTTTTCTATCGTCATGGGTTTG-
TTGCCAATTTCAGC-39; reverse: 59-GCTGAAATTGGCAA-
CAAACCCATGACGATAGAAAAAACTTGTG-39). Presence
of the mutation was confirmed by sequencing (Genewiz, South
Plainfield, NJ). The mammalian expression vector pCAGGS
containing a chicken b-actin promoter has been previously
described [42]. The expression plasmid encoding the PB1
Y499H mutation was generated by digestion of the pPolI PB1
Y499H and pCAGGS-PB1 plasmids with MfeI and AgeI enzymes
(New England Biolabs, Ipswich, MA). The digested insert
containing the Y499H mutation was inserted into the digested
pCAGGS-PB1 plasmid. Proper insertion and presence of
mutation was confirmed by sequencing (Genewiz). The pCAGGS
expression plasmid containing the D498Y mutation in the
influenza B/Yamagata/88 virus PB1 was generated by site-
directed mutagenesis using the following primers:
Forward: 59-GAATTTACAAGCATGTTCTATAGATATG-
GATTTGTATCTAATTTTGCAA
Reverse: 59-TTGCAAAATTAGATACAAATCCATATCTA-
TAGAACATGCTTGTAAATTC
Viruses
The influenza A/WSN/33 (H1N1) virus (WSN) was propagated
in MDCK cells for 2 days at 37uC. Influenza A/California/04/
2009 (H1N1) virus was propagated in MDCK cells for 3 days at
35uC. Influenza rA/Brevig Mission/1/1918 (H1N1) virus bearing
the HA segment from A/South Carolina/1/1918 was propagated
in MDCK cells for 2 days at 37uC. Experiments involving this
virus were conducted under Biosafety level 3-enhanced conditions
in accordance with the CDC guidelines. Influenza viruses A/
Puerto Rico/8/1934 (H1N1) (rPR8), A/Hong Kong/1/1968
(H3N2), A/Udorn/307/1972 (H3N2), A/USSR/90/1977
(H1N1), A/swine/Texas/ 4199-2/1998 (H3N2), and rA/Viet-
nam/1203/2004 (H5N1) bearing a mutated polybasic cleavage
site in the HA segment, and NDV-GFP were propagated in 10-
day old embryonated chicken eggs for 2 days at 37uC. Sendai virus
Cantell (SeV) was propagated in 8-day old embryonated chicken
eggs for 2 days at 37uC. Influenza B/Yamagata/16/1988 virus
was propagated in 8-day old embryonated chicken eggs for 3 days
at 33uC. Influenza rPR8 NS1-113 virus was propagated in 7-day
old embryonated chicken eggs for 2 days at 37uC [21]. The rescue
of NDV-GFP was previously described [43]. All influenza viruses
were titered by standard plaque assay in MDCK cells. Sindbis
virus (SinV) and vesicular stomatitis virus expressing the green
fluorescence protein (VSV-GFP) were kindly provided by John
Hiscott (McGill University, Montreal, QC, Canada) and were
grown and titered by plaque assay in VERO cells.
Recombinant influenza viruses were generated using the
influenza virus rescue protocol as previously described [30].
Briefly, 293T cells were transfected with eight pPolI constructs
expressing the PB1 (or PB1 Y499H), PB2, PA, NP, HA, NA, M,
and NS genomic segments as well as pCAGGS expression
plasmids encoding the PB1, PB2, PA, and NP proteins. Twenty-
four hours post transfection, MDCK cells were co-cultured with
the transfected 293Ts for an additional 24–48 hours, until
cytopathic effects were observed. Newly generated viruses were
collected and plaque-purified, and the presence of the mutation
was confirmed by sequencing.
Small molecular weight compounds
All compounds were provided by and screened at the National
Screening Laboratory for the Regional Centers of Excellence in
Biodefense and Emerging Infectious Diseases (NSRB) (Harvard
Medical School, Boston, MA). The libraries screened were the
following: Biomol ICCB Known Bioactives2 Library (480
compounds; BIOMOL, Plymouth Meeting, PA), NINDS custom
collection 2 (1,040 compounds; MicroSource Discovery Systems,
Gaylorsville, CT), Prestwick1 Collection (1,120 compounds;
Prestwick Chemical, Inc., Washington, DC), ActiMol Tim Tec 1
(8,518 compounds; TimTec Inc., Newark, DE), Asinex 1 (12,378
compounds; Asinex Corp., Winston-Salem, NC), Bionet 2 (1,700
compounds; Ryan Scientific, Mount Pleasant, SC), Chembridge 3
(10,560 compounds; ChemBridge Corp., San Diego, CA),
ChemDiv 2 (8,560 compounds; ChemDiv, Inc., San Diego, CA),
ChemDiv 4 (1,320 compounds; ChemDiv, Inc., San Diego, CA),
Enamine 2 (26,576 compounds; ENAMINE Ltd., Kiev, Ukraine),
Life Chemicals 1 (3,893 compounds; Life Chemicals Inc.,
Burlington, ON), Maybridge 4 (4,576 compounds; Maybridge
Ltd., Trevillett, England), Maybridge 5 (3,212 compounds;
Maybridge Ltd., Trevillett, England), Mixed Commercial Plate 5
(268 compounds from ChemDiv and Maybridge libraries),
Peakdale 2 (352 compounds; Peakdale Molecular Ltd. Chapel-
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220uC in desiccated storage containers. Compounds were
dissolved in 100% dimethylsulfoxide (DMSO) at 2 mg/mL for
the Prestwick1 library, 10 mM for the NINDS library, and 5 mg/
mL for the remaining libraries. The dilution factor for the screen
was 350 fold.
For secondary analyses, hit compounds were purchased directly
from the vendors indicated and dissolved in 100% DMSO. The
final concentration of DMSO in the culture medium did not
exceed 0.5%.
High-throughput screen assay
The screen was performed in duplicate using solid white 384-
well plates. The MDCK IFNb-luciferase cells were cultured to
90% confluency, washed with phosphate buffered saline (PBS)
(Invitrogen), trypsinized with 0.05% Trypsin-EDTA (Invitrogen),
and resuspended in phenol red-free DMEM growth medium
(Invitrogen) supplemented with 5% FBS, and 1% P/S at a
concentration of 2610
5 cells/mL. With the automated plate filler,
30 mL of the diluted MDCK IFNb-luciferase cell suspension was
seeded into each well of a 384-well plate (6000 cells/well), and
incubated at 37uC, 5% CO2 for 20 hours. Compounds (100 nL)
were then added using the Epson pin transfer robot (Epson
America, Long Beach, CA), and incubated at 37uC, 5% CO2 for
2 hours. Cells were then infected with rPR8 (MOI=10) by adding
5 mL of the virus inoculum (medium+1 mg/mL TPCK) directly
into the medium. Two columns on the right side of each plate
were reserved for controls and did not contain compounds. The
second to last column was infected with only rPR8 virus (negative
control) and the last column was infected with only rPR8 NS1-113
virus (positive control). Infection proceeded at 37uC, 5% CO2 for
18 hours prior to measuring luciferase production. 35 mL of the
Bright-Glo reagent (diluted 3 fold with PBS as described above)
was added to each well and the luminescence signal was measured
using the EnVision plate reader. Calculation of the Z-Score and
selection of hits are described in the ‘data analysis’ section.
Data analysis
To evaluate the robustness of our assays we calculated a Z9-
Factor [24]. The calculations were done according to the following
formula: Z9=12((3dpos+3dneg)/(mpos2mneg)), where mpos is the
mean signal for the positive control (rPR8 NS1-113 infection), mneg
is the mean signal for the negative control (rPR8 infection), dpos is
the standard deviation of the positive control, and dneg is the
standard deviation for the negative control. A reproducible Z9-
Factor.0.5 is considered optimal for HTS. The percent
coefficient of variation: %CV=dpos/mpos*100, the signal-to-
background ratio: S/B=mpos/mneg, and the signal-to-noise ratio:
S/N=(mpos2mneg)/((dpos)‘2+(dneg)‘2)‘1/2 were also calculated.
Analysis of the results obtained from the compound screen was
done in Microsoft Office Excel using a Z-Score calculation to
standardize each compound signal. The Z-Score formula indicates
how many standard deviations a particular compound is above or
below the mean of the plate, and is calculated as follows: Z-
Score=(x2m)/d, where x is the raw signal, m is the mean signal of
all the compound-containing wells of one plate, and d is the
standard deviation of all compound-containing wells of one plate.
Primary hits were identified by calculating a Z-score for each
compound and applying hit selection criteria: A compound was
considered a hit if one replicate had a Z-Score.3 and the other
replicate had a Z-Score of .2.5.
In cell viability assays, the relative metabolic activity of ATP was
calculated according to the following formula: % ATP=(x/
mneg)*100, where x is the raw signal for each compound, and mneg
is the mean signal for the negative control (DMSO-treated cells).
This calculation normalizes DMSO-treated cells (negative control)
to 100% ATP activity.
Analysis of the confirmation screen assay was done using a fold
induction calculation to normalize each compound signal. The
following formula was used: Fold Induction=x/mneg where x is the
raw signal for each compound, and mneg is the mean signal for the
negative control (either DMSO-treatment for compound treated
cells, or DMSO-treated infection (rPR8, WSN, or VSV) for
compound-treated infections). Confirmed hits were selected by
calculating the fold induction for each compound and applying
selection criteria: A compound was confirmed if it displayed a
dose-dependent effect with a minimum 5 fold induction, either in
the presence or absence of influenza virus (rPR8) infection.
Cell viability assay
The CellTiterGlo Cell Viability Assay (Promega) was used to
detect ATP levels as a function of cell viability, according to
manufacturer’s specifications. Cells were seeded into 96-well plates
(7500 cells/well) and incubated at 37uC, 5% CO2 for 24 hours.
Culture medium was then replaced with 50 mL of fresh medium
containing compound (serially diluted), and this was further
incubated for 48 hours. Luciferase production was measured by
adding 50 mL of CellTiterGlo reagent (diluted 2 fold with PBS) to
each well, and the luminescence signal was read using the
Beckman plate reader. Relative metabolic activity of ATP was
calculated as described in the ‘data analysis’ section.
Confirmation screen assay
Confirmation of the primary hits was done with re-ordered
compounds from commercial vendors, as described in the ‘small
molecular weight compounds’ section. MDCK IFNb-luciferase
cells were plated into 96-well plates with 50 mL of cells (3610
5
cells/mL), and incubated for 20 hours. Ten serial dilutions of
compounds were made in 100% DMSO, starting from the highest
non-toxic soluble concentration. Serial dilutions in DMSO were
further diluted 200 fold in post-infection medium (DMEM
supplemented with 0.1% FBS, 1% P/S, 0.5% BSA, 1 mg/mL
TPCK) to obtain a final 0.5% DMSO concentration. These were
then added to cells in a 96-well plate excluding the outside wells
(60 wells total), and incubated for 2 hours prior to infection. The
top half of the plate (30 wells) was left uninfected, whereas the
bottom half was infected with rPR8 (MOI=10), WSN (MOI=1),
or VSV (MOI=0.01) by adding 10 mL of the virus inoculum (PBS
supplemented with 0.5% BSA and 1% P/S) directly to the
medium. Each condition was tested in triplicate. Mock plates
infected with rPR8 NS1-113 or without infection were used as
controls. Infection proceeded at 37uC, 5% CO2 for 18 hours prior
to measuring luciferase production by adding 50 mL of Bright-Glo
reagent (diluted 3 fold with PBS) to each well. The luminescence
signal was measured using the Beckman plate reader. Fold
induction was calculated as described in the ‘data analysis’ section.
Infection of cells in the presence of inhibitors
To test the effects of compounds on multi-cycle influenza virus
replication, cells were seeded into 6-well plates at 5610
5 cells/well
or 12-well plates at 2610
5 cells/well and incubated at 37uC, 5%
CO2 for 24 hours. Cells were then washed with PBS and infected
with the indicated virus in PBS/0.5% BSA infection medium at
MOI=0.01 (unless otherwise indicated) in a 200 mL inoculum.
After 1 hour incubation at room temperature, the virus inoculum
was aspirated, cells were washed with PBS, and post-infection
medium (with 1 mg/mL TPCK) containing compound was added
to cells and incubated for 48 hours during influenza virus and
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influenza viruses were determined by standard plaque assay in
MDCK cells. Viral titers of VSV and SinV were determined by
standard plaque assay in VERO cells.
To test the effect of ASN2 on IFN induction, cells were infected
at an MOI=1, and incubated with post-infection medium
containing compound for 24 hours. Final concentration of
ASN2 was 50 mM, unless indicated.
RNA isolation
RNA extraction of cells for subsequent qRT-PCR analysis was
performed using the RNeasy Mini Kit (Qiagen, Valencia, CA)
according to manufacturer’s specifications. RNA extraction for
deep sequencing was performed using the TRIzol Reagent
(Invitrogen) according to manufacturer’s specifications. RNA
extraction of viral RNA was performed using the QIAamp Viral
RNA Mini Kit (Qiagen) according to manufacturer’s specifica-
tions. RNA yields were evaluated using a Nanodrop spectropho-
tometer (Nanodrop technologies, Wilmington, DE).
RT-PCR and quantitative RT-PCR (qRT-PCR)
A two-step qRT-PCR was performed to analyze cellular and
viral genes. First-strand synthesis of isolated RNA was done by
reverse transcription using Superscript III reverse transcriptase
(Invitrogen), Random Primers (Invitrogen), and RNase Out
(Invitrogen), according to manufacturer’s specifications. Resulting
cDNA was diluted to 2–5 ng/mL in PCR-grade water and used for
quantitative PCR using LightCycler 480 SYBR Green I Master
reagent (Roche), and the LightCycler 480 instrument (Roche),
according to manufacturer’s specifications. Analysis of results were
done using the 2
2DDCT (two delta delta CT) method [44]. We
calculated DDCT values over replicates using a-tubulin as the
endogenous housekeeping gene and DMSO-treated uninfected
(MOCK) or DMSO-treated infected samples as the calibrator in
respective experiments. Values represent the fold difference for
each condition as compared with DMSO-treated uninfected or
DMSO-treated infected samples. Error bars indicate 6 standard
deviation of fold induction.
For sequencing of different influenza A virus segments of the
ASN2 resistant virus and recombinant influenza viruses, a one-step
RT-PCR was performed using the Superscript III One-Step RT-
PCR System with Platinum Taq High Fidelity (Invitrogen),
according to manufacturer’s specifications.
Antiviral bioassay
To test the biological activity of cytokines released during ASN2
treatment of infected cells, an antiviral bioassay was performed as
previously described with some differences [45]. A549 cells were
plated into 96-well plates with 50 mL of cells (1610
4 cells/well),
and incubated at 37uC, 5% CO2 for 24 hours. The culture
medium was replaced with post-infection medium containing
compound and 1 mg/mL TPCK. After 2 hours incubation, these
were infected with rPR8 (MOI=10) or WSN (MOI=1) by adding
10 mL of virus inoculum directly into the medium. Sendai virus
(SeV) infection was used as a positive control for interferon
induction. At 18 hours post infection, supernatants were harvested
and virus present in the supernatant was UV inactivated by
placing the 96-well plate in a UV chamber delivering 200 J/cm
2.
Two-fold dilutions of the inactivated supernatants were added to
fresh VERO cells previously seeded in 96-well plates. Following a
24 hour incubation, VERO cell supernatants were aspirated, and
cells were infected with 50 mL NDV-GFP diluted in OptiMEM.
(The concentration of NDV-GFP used was previously determined
to yield 90% GFP expression at 24 hours). GFP was visualized
24 hours post infection by fluorescence microscopy and quantified
using the Beckman plate reader.
Percent inhibition of NDV-GFP induced by the supernatants
was calculated using the following formula: % inhibi-
ton=1002(x/mneg *100), where x is the raw signal for each
treatment, mneg is the mean signal for the negative control
(MOCK: untreated and NDV-GFP infected cells).
Deep sequencing
Total RNA was isolated from infected cells treated with ASN2
or DMSO as previously described in the ‘RNA isolation’ section.
Processing of the RNA and subsequent sequencing was performed
by the Mount Sinai sequencing facility using the Illumina Genome
Analyzer (Illumina, San Diego, CA). Briefly, mRNA was isolated
using oligo(dT)-coated beads, and subsequently fragmented using
the Covaris RNA Shearing kit (Covaris, Woburn, Massachusetts).
After precipitation of RNA, first strand cDNA synthesis was
performed with Superscript II reverse transcriptase (Invitrogen),
Random Primers (Invitrogen), and RNase Inhibitor (Invitrogen).
Second strand cDNA synthesis, end repair, A-tailing, and adaptor
ligations were done using the Illumina Sample Prep Kit (Illumina).
Elution of cDNA fragments and gel purification was done using
the MinElute Gel Extraction Kit (Qiagen). A 200–300 bp gel piece
was cut prior to isolation of cDNA using the QIA Quick Gel
Extraction Kit (Qiagen). PCR amplification and purification of
fragments were done prior to sequencing on the Illumina platform.
Sequences were mapped to both human and influenza virus
genomes. Relative abundance was normalized to the values
obtained for the GAPDH mRNA, and average ratios between
infected cells treated with ASN2 or DMSO were calculated. The
ratios represent fold induction of ASN2 treatment over DMSO
treatment.
Western blot
Cells were washed twice with cold PBS and lysed in a 0.5%
Nonidet P-40 lysis buffer. Samples were run on 4–20% precast
gradient gels (Bio-Rad, Hercules, CA) and transferred onto
polyvinylidenefluoride (PVDF) membranes (GE Healthcare,
Buckinghamshire, UK). GAPDH, PB1, NP, NS1, M1, and M2
proteins were detected using the rabbit polyclonal anti-glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) antibody (Sigma), a
rabbit polyclonal PB1 antibody (generated by peptide immuniza-
tion), a mouse monoclonal NS1 antibody (clone 1A7, Mount Sinai
Hyridoma Facility), a mouse monoclonal NP antibody (clone
28D8, Mount Sinai Hyridoma Facility), a mouse monoclonal M1
and M2 antibody (clone E10, Mount Sinai Hyridoma Facility),
and horseradish peroxidase-conjugated secondary antibodies (GE
Healthcare).
Animal experiments
Ethics statement. This study was carried out in strict
accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Mount Sinai School of
Medicine Institutional Animal Care and Use Committee (IACUC)
(Animal Assurance No. A3111-01). Mice were euthanized at the
end of the experiment according to these guidelines and all efforts
were made to minimize suffering.
Six to eight week old female BALB/c mice (Jackson Laboratory,
Bar Harbor, ME) were separated into groups of 9 mice.
Pretreatment was done by administering one dose of ASN2
(33.3 mg/kg), oseltamivir (0.5 mg/kg) or solvent (33% DMSO,
33% PBS, and 33% Labrafil (Gattefosse, Paramus, NJ)) intraper-
itoneally (IP) 8 hours and 1 hour prior to infection. Mice were
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infected intranasally with influenza A/WSN/33 virus (5MLD50).
ASN2 (100 mg/kg/day), oseltamivir (1.5 mg/kg/day), and re-
spective solvent treatments proceeded every 8 hours for 8 days.
Bodyweight and survival was monitored daily. Three mice from
each group were euthanized on days 3 and 8 post infection and
viral lung titers were determined by plaques assay.
In vitro liver microsome assay
This analysis was performed by Cyprotex. Pooled Balb/C
mouse liver microsomes (final protein concentration 0.5 mg/ml),
0.1 M phosphate buffer pH 7.4 and ASN2 (final concentration
3 mM in 0.25% DMSO) were pre-incubated at 37uC prior to
addition of NADPH (final concentration 1 mM) to initiate the
reaction. Controls included samples that lacked NADPH and
samples that contained control compounds to be used as internal
standards. Samples were incubated for 0, 5, 15, 30 and 45 min.
The reactions were stopped by the addition of 50 ml methanol.
Protein was precipitated by centrifugation at 25000 rpm for
20 min at 4uC and the supernatants were analyzed by LC-MS/
MS to detect and quantify the compounds at each time-point.
Intrinsic clearance and half-life were calculated from a plot of the
peak area ratio (ASN2 peak area/internal standard peak area)
against time.
IFNb reporter assays
For IFNb reporter assays, A549 cells were transfected with
lipofectamine LTX (Invitrogen). Transfections were done in 24-
well plates at cell concentrations of 2610
5 cells/well for A549 cells,
at a lipid:DNA ratio of 2:1. 125 ng of IFNb-LUC reporter, 50 ng
pRL-TK reporter, and 325 ng of empty pCAGGS vector or
pCAGGS-NS1 were transfected into one well using 1 mL
transfection reagent in 75 mL Opti-MEM. Incubation of lipid
and DNA was done at room temperature for 30 minutes prior to
adding the transfection complex directly to cells containing regular
growth medium. 24 hours post transfection, cells were washed and
infected with influenza viruses (as indicated) at an MOI=1 for
1 hour prior to addition of post infection medium containing
DMSO or ASN2. Infections proceeded for 24 hours prior to
assaying for luciferase activity using the Dual-Glo Luciferase Assay
kit (Promega), according to manufacturer’s specifications.
Plaque-reduction assay
Cells were seeded into 6-well plates until 100% confluency was
achieved. The indicated viruses were diluted 10
4 to 10
6 fold from
their stock concentration. Each dilution was used to infect one 6-
well plate at a 200 mL inoculum, and incubated at room
temperature for 1 hour. Virus inoculum was aspirated and plaque
overlay medium containing DMSO or ASN2 (50 mM and 25 mM)
was added to cells, which were incubated at 37uC, 5% CO2 for
48–72 hours. Plaques were visualized by immunostaining with an
NP antibody and horseradish peroxidase-conjugated secondary
antibody.
Influenza virus minigenome assays
For influenza A virus minigenome reporter assays, A549 cells
were transfected with lipofectamine LTX (Invitrogen). Transfec-
tions were done in 24-well plates at cell concentrations of 2610
5
cells/well for A549 cells, at a lipid:DNA ratio of 2:1. 75 ng of
WSN NP_LUC reporter, 50 ng pRL-TK reporter, 50 ng of WSN
PB1, WSN PB2, and WSN PA expression plasmids, and 100 ng
WSN NP expression plasmid (or empty vector for negative control)
were co-transfected with 0.75 mL transfection reagent in 0.75 mL
Opti-MEM. Incubation of lipid and DNA was done at room
temperature for 30 minutes prior to adding the transfection
complex directly to cells containing post infection medium
(without TPCK) supplemented with ASN2 or DMSO. 24 hours
post transfection, cells were lysed and luciferase production was
measured with the Dual-Glo Luciferase Assay kit (Promega),
according to the manufacturer’s specifications. For the influenza B
virus minigenome assay a plasmid encoding the chloramphenicol
acetyl transferase (CAT) gene flanked by the non-coding regions
from the NS segment of influenza B/Lee/40 virus (pPOLI-B/
Lee/40 NS-CAT) was used [46]. The PB1, PB2, PA and NP
expression constructs were derived from influenza B/Yamagata/
88 virus. CAT expression was assayed by ELISA (Roche).
Primer extension assay
A549 cells were seeded into 10 cm dishes (Corning) at 2.5610
6
cells/dish in regular growth medium and incubated at 37uC, 5%
CO2 for 24 hours. Cell culture medium was then replaced with
post-infection medium (with 1 mg/mL TPCK) containing DMSO,
ASN2 (50 mM, 25 mM, and 12.5 mM) or ribavirin (100 mM) for
4 hours prior to infection. Cells were then washed with PBS and
infected with WSN in PBS/0.5% BSA infection medium
(MOI=5) in a 1 mL inoculum. After 1 hour incubation at room
temperature, virus inoculum was aspirated, cells were washed with
PBS, and post-infection medium (with 1 mg/mL TPCK) contain-
ing the respective compounds was added to cells and incubated for
6 hours. RNA was extracted using the RNeasy Mini Kit (Qiagen).
Primer labeling, primer extension reaction, and gel analysis of
products were performed using the Primer Extension System –
AMV Reverse Transcriptase kit (Promega) according to the
manufacturer’s specifications. Primers used for primer extension
can be found in [34]. Resulting blots were visualized with the
phosphorimager Typhoon Variable Mode Imager (GE Heathcare,
Piscataway, NJ) and quantified using ImageJ software.
Supporting Information
Figure S1 Schematic of high-throughput compound screen. In
the primary screen (1), MDCK IFNb-luciferase cells were seeded
into 384-well plates and incubated for 20 hours prior to pin
transfer of compounds. Two hours later, wells were infected with
influenza A/PR/8/34 virus (MOI=10) for 18 hours before
luciferase activity was measured. Two columns in each plate were
reserved for the controls and did not contain compounds. The
second to last column was infected with wild type PR8 virus only
(negative control) and the last column was infected with PR8 NS1-
113 virus only (positive control). Primary hits were identified upon
calculation of a Z-Score for each compound and application of the
hit criteria as indicated. The secondary screen (2) was performed
with 250 compounds out of the 264 identified hits. This screen was
done in a 96-well format, and included the secondary assays
shown. Confirmed hits (27) were selected based on the
confirmation criteria indicated. These hits were divided into two
groups: compounds that induce IFNb independently of virus
infection, and compounds that required virus infection to induce
IFNb. ASN2 was selected as the lead compound (3) for further
evaluation.
(TIF)
Figure S2 Replication of influenza A virus is required for
induction of interferon upon ASN2 treatment. (A) qRT-PCR
analysis of IFNb and ISG56 mRNA in A549 cells infected with A/
WSN/33 (MOI=1) and treated with decreasing concentrations of
ASN2 (50-12.5 mM) for 24 hours. (B) qRT-PCR analysis of IFNb
and ISG56 mRNA in A549 cells infected with UV-inactivated A/
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ASN2 (50-12.5 mM) for 24 hours. IFNb treatment (50 IU/mL)
was used as a positive control. Values were normalized to a-
tubulin for each sample and are represented as fold induction over
uninfected DMSO-treated sample. Error bars reflect standard
deviation of fold change.
(TIF)
Figure S3 ASN2 preferentially inhibits the production of viral
mRNA from smaller influenza virus genome segments. (A) Deep
sequencing analysis of influenza virus mRNA in A549 cells
infected with A/WSN/33 (MOI=1) and treated with DMSO or
ASN2 (50 mM) for 24 hours. Y axis represents the total number of
reads for each particular sequence (50 nt long), and X axis
represents the position of each read in the viral genome. (B)
Analysis of sequence reads from part A. Values were normalized to
total reads for each sample and are represented as ASN2/DMSO
ratio.
(TIF)
Figure S4 ASN2 is a unique interferon-inducing antiviral
compound. qRT-PCR analysis of IFNb mRNA in A549 cells
infected with influenza A/WSN/33 virus (MOI=1) and treated
with ASN2 (50 mM) or A3 (10 mM) for 24 hours. Values were
normalized to a-tubulin for each sample and are represented as
fold induction over uninfected DMSO-treated sample. Error bars
reflect standard deviation of fold change.
(TIF)
Table S1 Transcriptional profile of genes induced by ASN2 in
influenza virus infected cells.
(TIF)
Table S2 Amino acid conservation at position 499 of the
influenza A virus PB1 protein.
(TIF)
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